Best for Longevity
Best NAC for Longevity
Top 30 products ranked · Reviewed May 2026 · 600–1800 mg clinical dose
Why NAC for Longevity
NAC plays a important role in longevity. NAC is a precursor to glutathione, the body's primary intracellular antioxidant. Supports liver detoxification, respiratory health, and cellular defense against oxidative stress.
What dose to look for
Clinical studies typically use 600–1800 mg of nac. Most studies use 600–1200 mg/day. Higher doses (up to 1800 mg) used in some clinical contexts. Often taken in divided doses. Products below this range may not deliver meaningful results.
What the research says
NAC has moderate clinical evidence for longevity benefits. Precursor to glutathione with established medical use for acetaminophen toxicity and mucolytic therapy Learn more
Clinical research on NAC (N-Acetylcysteine)
LOW — mechanistic only for cellular aging; no human trials on senescence, mitochondrial, or NAD+ endpoints in this category · Clinical trials used roughly 600 mg/day (COPD mucolytic) up to 2,000–3,000 mg/day (psychiatric augmentation) — for unrelated endpoints. No validated dose exists for any cellular-aging or longevity outcome.
- •Mechanism only: NAC supplies cysteine, the rate-limiting substrate for glutathione synthesis — the cell's primary endogenous antioxidant and the plausible link to oxidative-stress theories of aging. No RCT has tested NAC against cellular-aging, cellular senescence, mitochondrial function, or NAD+ endpoints in humans.
- •The 'glutathione booster' claim is weaker than marketed: in healthy people, measured glutathione increases from oral NAC are modest in the few studies that quantified them. NAC demonstrably restores glutathione mainly in depleted/pathological states — e.g. the IV acetaminophen-overdose antidote protocol (Smilkstein 1991, n=179) — which is emergency medicine, not a model for longevity supplementation. PubMed
- •No human longevity, lifespan, or anti-senescence trial exists for NAC. Its actual RCT evidence base sits in unrelated categories (COPD mucolytic, and small adjunctive psychiatric trials in bipolar depression, schizophrenia and trichotillomania — with a null result in OCD augmentation), none of which measure cellular-aging outcomes — so a cellular-health rating rests entirely on mechanistic plausibility, not replicated clinical effect.